Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?

Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?

ABSTRACT: Background: Concerns have been raised that the risk of severe acute respiratory syndrome coronavirus 2 infection, or more severe or critical coronavirus disease 2019 (COVID-19), may be higher in immunocompromised individuals receiving immunomodulatory therapies compared with immunocompete...

Full description

Bibliographic Details
Main Authors: Samantha Howland, MPharm, J. Jasper Deuring, PhD, Xiaofeng Zhou, PhD, Yan Chen, MD, PhD, Licia MH Mota, MD, Ryan C. Ungaro, MD, MS
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Current Therapeutic Research
Subjects:
gastroenterology
immunosuppressive treatment
rheumatology
virology
Online Access:http://www.sciencedirect.com/science/article/pii/S0011393X21000175

Internet

http://www.sciencedirect.com/science/article/pii/S0011393X21000175

Similar Items